摘要

Objectives: To evaluate the safety and efficacy of different doses of placental peptide through a BALB/c mouse model of atopic dermatitis induced by oxazolone (OXA). Introduction: In recent years, placental extract (PE) extracted from mammalian tissues has been found to have various positive effects on the skin. According to "Guidelines for the Diagnosis and Treatment of Sensitive Skin (SS) in China" 2024 edition, SS is a syndrome in which multiple subjective and objective symptoms appear after receiving minor external stimuli and is more common in the face. Currently research suggests that the occurrence of SS is a complex process involving the skin barrier, nerves, blood vessels and immune inflammation. Therefore, PE may become a method for treating SS. Materials / method: Sensitize the abdominal skin of mice with 3% OXA one week in advance, and then continuously stimulate the back skin and right ear of mice with 0.5% OXA for three weeks, while administering medication treatment. Evaluate the inhibitory effect of placental peptides on atopic dermatitis by evaluating mouse ear thickness, ear swelling rate, back skin inflammation score, as well as ear tissue weighing, skin pathological staining, and changes in serum and skin inflammatory factors at the experimental endpoint. Results: 1. The animals in Group L applied placental peptide 50 μL, 100 μL and 200 μL were well tolerated and did not experience any adverse reactions; The animals in the dexamethasone group showed moderate weight loss, indicating a certain level of toxicity. 2. The therapeutic effect of the test substance in a BALB/c mouse model of atopic dermatitis: placental peptide 50 μ L,100 μ L and 200 μ L showed a certain dose-dependent inhibition of delayed hypersensitivity in mice, and volume of 200μL of placental peptide is equivalent to a concentration of 1mg/mL of dexamethasone. Conclusion: Placental peptides inhibit inflammation through immune regulation which could be a new therapy for SS. Although animal experiments have validated the effectiveness and safety of placental peptides, clinical trials are needed to demonstrate its therapeutic effects in SS.